Published in Dig Dis Sci on September 01, 2002
Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis (2012) 1.24
Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab (2012) 1.12
Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol (2010) 0.99
Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. Mediators Inflamm (2005) 0.84
Hyperammonemia results in reduced muscle function independent of muscle mass. Am J Physiol Gastrointest Liver Physiol (2015) 0.84
A half century (1961-2011) of applying microsurgery to experimental liver research. World J Hepatol (2012) 0.80
Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin. Am J Physiol Gastrointest Liver Physiol (2011) 0.80
Treatment to improve nutrition and functional capacity evaluation in liver transplant candidates. Curr Treat Options Gastroenterol (2014) 0.78
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Alcoholic liver disease. Hepatology (2010) 5.04
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol (2013) 2.14
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology (2013) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol (2006) 1.91
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med (2003) 1.60
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol (2010) 1.58
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Racial differences in hepatitis C treatment eligibility. Hepatology (2011) 1.28
Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis (2002) 1.27
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Measuring protein synthesis using metabolic ²H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem (2011) 1.16
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem (2010) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol (2002) 1.12
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Gender differences in the regulation of amino acid metabolism. J Appl Physiol (1985) (2003) 1.03
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol (2013) 1.01
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int (2013) 1.00
Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol (2010) 0.99
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci (2011) 0.94
Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol (2010) 0.93
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int (2009) 0.91
Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2009) 0.90
The liver in other (nondiabetic) endocrine disorders. Clin Liver Dis (2002) 0.90
Theories of the pathogenesis of hepatic encephalopathy. Clin Liver Dis (2012) 0.89
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.89
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. N Engl J Med (2006) 0.89
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol (2014) 0.89
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol (2012) 0.88
Pleural effusion and pseudocyst. Clin Gastroenterol Hepatol (2012) 0.88
Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism (2008) 0.88
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci (2012) 0.88
New mechanism of selective killing of activated hepatic stellate cells. Hepatology (2003) 0.87
Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol (2012) 0.87
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Long-term management of alcoholic liver disease. Clin Liver Dis (2005) 0.86
The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis (2013) 0.85
Steroids or cocktails for alcoholic hepatitis. J Hepatol (2006) 0.85
Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. J Hepatol (2006) 0.85
Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2013) 0.84
Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci (2015) 0.83
The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy. Gastroenterology (2008) 0.83
Is poor quality of life always present with minimal hepatic encephalopathy? Liver Int (2011) 0.83
Recurrent Intentional Foreign Body Ingestion: An Endoscopist's Dilemma. Gastroenterol Hepatol (N Y) (2012) 0.82